Literature DB >> 20660330

High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera.

Yu-Min Yeh1, Yi-Lin Chen, Hsieh-Yin Cheng, Wu-Chou Su, Nan-Haw Chow, Tsai-Yun Chen, Chung-Liang Ho.   

Abstract

We examined the occurrence of JAK2(V617F) and JAK2 exon 12 mutations in a clinical cohort of polycythemia vera (PV) in Taiwan. Of 22 patients with PV, 17 (77%) had the V617F mutation, and all 5 V617F-negative patients (23%) had the exon 12 mutation. We found 3 different exon 12 mutations: 3 N542-E543del, 1 F537-K539delinsL, and 1 novel mutation, I540-E543delinsKK. Patients with V617F showed significantly higher WBC and platelet counts at diagnosis than patients with exon 12 mutations (P = .021 and P = .038, respectively). We report a surprisingly high incidence of exon 12 mutations in Taiwanese patients with PV, a result quite different from reports in the Western literature (P = .001). Our data suggest that exon 12 mutation of JAK2 in patients with PV may have an uneven geographic distribution. A clinical laboratory providing the V617F test alone may risk missing a substantial number of patients with PV in areas with a high incidence of exon 12 mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660330     DOI: 10.1309/AJCPK7KGOWPHYWM0

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

Review 1.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

2.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

3.  JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.

Authors:  Madhavi Maddali; Uday Prakash Kulkarni; Niveditha Ravindra; Ekta Jajodia; Arun Kumar Arunachalam; Hemamalini Suresh; Arvind Venkatraman; Biju George; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Ann Hematol       Date:  2020-04-10       Impact factor: 3.673

4.  Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms.

Authors:  Shu-Peng Zhang; Hui Li; Ren-Sheng Lai
Journal:  Oncol Lett       Date:  2014-12-12       Impact factor: 2.967

5.  The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Xinju Zhang; Xiao Xu; Yuming Chen; Tingting Hu; Zhihua Kang; Shibao Li; Hua Wang; Weiwei Liu; Xiaochao Ma; Ming Guan
Journal:  J Hematol Oncol       Date:  2014-07-15       Impact factor: 17.388

6.  [Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera].

Authors:  D Liu; P H Zhang; Z F Xu; J Ma; T J Qin; S Q Qu; X J Sun; B Li; L J Pan; Y J Jia; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.